Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Trazodone hydrochloride
Drug ID BADD_D02267
Description Trazodone is triazolopyridine derivative from the serotonin receptor antagonists and reuptake inhibitors (SARIs) class of antidepressants.[A181180] It is used in adults and has been shown to be comparable in efficacy to other drugs such as tricyclic antidepressants (TCAs), selective serotonin reuptake inhibitors (SSRIs), and serotonin-norepinephrine receptor inhibitor (SNRIs) in the treatment of depression.[T646] A unique feature of this drug is that it does not promote the anxiety symptoms, sexual symptoms, or insomnia, which are commonly associated with SSRI and SNRI therapy.[T646] Trazodone acts on various receptors, including certain histamine, serotonin, and adrenergic receptors, distinguishing it from other antidepressants that cover a narrow range of neurotransmitters.[T646] It was initially granted FDA approval in 1981.[L3484]
Indications and Usage Trazodone is indicated for the treatment of major depressive disorder (MDD).[L3484] It has been used off-label for adjunct therapy in alcohol dependence, and off-label to treat anxiety and insomnia.[L3484] It may also be used off-label to treat symptoms of dementia, Alzheimer’s disease, schizophrenia, eating disorders, and fibromyalgia due to its effects on various neurotransmitter receptors.[A31634]
Marketing Status approved; investigational
ATC Code N06AX05
DrugBank ID DB00656
KEGG ID D00820
MeSH ID D014196
PubChem ID 62935
TTD Drug ID D00USF
NDC Product Code 16729-299; 53002-1105; 60505-2654; 60687-454; 61919-613; 68071-2822; 69584-884; 70518-2793; 70518-2973; 0555-0711; 70934-818; 71610-514; 82982-047; 0904-6869; 59651-704; 59651-706; 13668-331; 16729-302; 42291-869; 50111-450; 50111-560; 53002-4105; 55154-8087; 57664-053; 60760-806; 63187-680; 68071-2996; 68788-7137; 70518-3403; 71205-630; 71335-1575; 71610-530; 0615-8386; 13668-330; 13668-333; 51655-662; 53489-511; 60505-2653; 68071-4410; 68788-7118; 70771-1129; 70771-1131; 71205-505; 71335-1630; 55700-739; 68382-806; 69584-885; 70771-1130; 71335-0742; 71335-2084; 72789-079; 50090-4825; 50090-6121; 53002-1132; 55700-810; 57664-014; 60505-2655; 60687-443; 61919-386; 61919-473; 61919-631; 63187-133; 67296-2049; 68071-5187; 68382-805; 70518-3426; 70518-3756; 71205-551; 71205-815; 71335-0705; 71335-1483; 71610-529; 0615-8371; 80425-0298; 51927-0215; 45865-431; 51655-366; 51655-986; 55700-844; 60687-432; 67296-1438; 68071-2959; 68382-808; 70518-1204; 70518-2929; 70518-3479; 70771-1128; 70934-817; 71205-568; 71335-0730; 80425-0302; 0904-7212; 13107-081; 13107-082; 16729-301; 50090-2373; 53002-3132; 55154-8085; 70518-2180; 0615-8339; 72789-168; 82053-002; 13107-080; 13668-332; 16729-300; 42291-868; 50111-561; 51655-658; 63187-377; 71610-511; 38779-0559; 59651-707; 62207-019; 13107-079; 53002-2132; 53489-510; 55700-957; 60505-2659; 68382-807; 70518-3082; 71610-525; 72789-154; 80425-0326; 0904-6868; 24823-911; 46014-1118; 59651-705; 50090-4283; 50090-5218; 55700-855; 63187-086; 68788-7166; 70518-3290; 71205-574; 71610-513; 71610-537; 58159-072; 65015-602; 65085-0014; 42291-829; 43353-973; 43353-974; 50090-2374; 50268-776; 53489-517; 55700-921; 57664-026
UNII 6E8ZO8LRNM
Synonyms Trazodone | Tradozone | AF-1161 | AF 1161 | AF1161 | Deprax | Desyrel | Gen-Trazodone | Gen Trazodone | Molipaxin | Novo-Trazodone | Novo Trazodone | Trittico | PMS-Trazodone | PMS Trazodone | Ratio-Trazodone | Ratio Trazodone | RatioTrazodone | Thombran | Trazodon Hexal | Trazodon-Neuraxpharm | Trazodon Neuraxpharm | TrazodonNeuraxpharm | Trazodone Hydrochloride | Trazon | Apo-Trazodone | Apo Trazodone | Nu-Trazodone | Nu Trazodone
Chemical Information
Molecular Formula C19H23Cl2N5O
CAS Registry Number 25332-39-2
SMILES C1CN(CCN1CCCN2C(=O)N3C=CC=CC3=N2)C4=CC(=CC=C4)Cl.Cl
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Hypoaesthesia23.03.03.081; 17.02.06.023--Not Available
Hypomania19.16.02.001--Not Available
Hypotension24.06.03.002--
Increased appetite14.03.01.003; 08.01.09.027--Not Available
Insomnia19.02.01.002; 17.15.03.002--
Jaundice23.03.03.030; 09.01.01.004; 01.06.04.004--Not Available
Leukocytosis01.02.01.002--
Libido decreased21.03.02.005; 19.08.03.001--
Libido increased21.03.02.007; 19.08.03.002--
Malaise08.01.01.003--
Memory impairment17.03.02.003; 19.20.01.003--
Menstruation irregular05.05.01.008; 21.01.01.005--
Methaemoglobinaemia01.05.01.002--
Muscle twitching15.05.03.005--Not Available
Musculoskeletal pain15.03.04.007--
Myocardial infarction24.04.04.009; 02.02.02.007--
Nail discolouration23.02.05.001--
Nausea07.01.07.001--
Nervousness19.06.02.003--Not Available
Nightmare19.02.03.003--Not Available
Ocular hyperaemia06.04.05.004--Not Available
Oedema14.05.06.010; 08.01.07.006--Not Available
Orthostatic hypotension24.06.03.004; 17.05.01.020--Not Available
Palpitations02.11.04.012--
Paraesthesia23.03.03.094; 17.02.06.005--
Paranoia19.05.01.005--Not Available
Pollakiuria20.02.02.007--
Priapism24.04.12.007; 21.03.01.005--Not Available
Pruritus23.03.12.001--
Psoriasis10.02.01.036; 23.03.14.002--Not Available
The 3th Page    First    Pre   3 4 5    Next   Last    Total 5 Pages